Biogen: all 548 studies

Page 4 of 6. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• Study of Utilization Patterns of Dimethyl Fumarate in GermanyCompletedNCT02969304
• Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074TerminatedNCT02957617Phase 2
• New Formulation and Food Effect Study of BIIB074CompletedNCT02951221Phase 1
• Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral RadiculopathyCompletedNCT02935608Phase 2
• A Phase 2a Study of BIIB074 in the Treatment of ErythromelalgiaCompletedNCT02917187Phase 2
• Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)No longer availableNCT02865109
• Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing ProcessesCompletedNCT02833142Phase 1
• PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian ParticipantsCompletedNCT02831517Phase 1
• A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy ParticipantsCompletedNCT02829541Phase 1
• Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy ParticipantsCompletedNCT02782975Phase 1
• Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT02776072
• Absorption, Metabolism, and Excretion Study of BIIB074CompletedNCT02751905Phase 1
• Effect of Itraconazole on the Pharmacokinetics of BIIB074CompletedNCT02698267Phase 1
• Clinical Disease Activity With Long Term Natalizumab TreatmentCompletedNCT02677077
• A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy AdultsCompletedNCT02666963Phase 1
• MSPT Device Usability StudyCompletedNCT02664324
• Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003TerminatedNCT02658916Phase 1
• Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese ParticipantsCompletedNCT02641041Phase 1
• Methodology Study of Novel Outcome Measures to Assess Progression of ALSCompletedNCT02611674
• Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012CompletedNCT02579681Phase 3
• Brimonidine Tartrate for the Treatment of Injection Related ErythemaWithdrawnNCT02568111Phase 4
• Single Ascending Doses of BIIB063 in Healthy VolunteersTerminatedNCT02555085Phase 1
• Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy SubjectsCompletedNCT02551497Phase 1
• Systemic Sclerosis Clinical and Biomarker StudyWithdrawnNCT02531009
• Single-Dose Study of a New Formulation of BIIB061CompletedNCT02521545Phase 1
• Tecfidera Lymphocyte Chart ReviewCompletedNCT02519413
• Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple SclerosisWithdrawnNCT02472938Phase 4
• Tecfidera and the Gut MicrobiotaCompletedNCT02471560Phase 4
• Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear PalsyCompletedNCT02460094Phase 1
• Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's DiseaseCompletedNCT02459886Phase 1
• Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's DiseaseCompletedNCT02434718Phase 1
• Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)WithdrawnNCT02428218Phase 3
• A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's SyndromeCompletedNCT02422407
• Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With NatalizumabCompletedNCT02386566
• PK & Tolerability of CNV1014802 in Young and Elderly Healthy VolunteersCompletedNCT02359344Phase 1
• Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)TerminatedNCT02323269
• A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy SubjectsCompletedNCT02294851Phase 1
• Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment BatteryCompletedNCT02283918
• Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy VolunteersCompletedNCT02269930Phase 1
• Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon TherapyWithdrawnNCT02234869Phase 4
• Plegridy Observational ProgramCompletedNCT02230969
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult VolunteersCompletedNCT02228707Phase 1
• A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy AdultsCompletedNCT02201849Phase 1
• A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial ManufacturersCompletedNCT02171208Phase 1
• Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)CompletedNCT02159573
• Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02142205Phase 4
• Natalizumab Subcutaneous Immunogenicity and Safety StudyTerminatedNCT02142192Phase 2
• Safety and Efficacy in Pediatric MS Patients Prescribed TysabriCompletedNCT02137109
• Pilot Tape Harvesting StudyCompletedNCT02125695
• A Multiple Dose Safety Study of PEG-IFN in Healthy VolunteersCompletedNCT02125578Phase 1
• Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus ErythematosusCompletedNCT02106897Phase 1
• Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl FumarateWithdrawnNCT02090348Phase 4
• Tolerability and Quality of Life Study in Participants Who Switched to Avonex PenCompletedNCT02076841
• Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food EffectCompletedNCT02071121Phase 1
• An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)CompletedNCT02052791Phase 1
• Dimethyl Fumarate (DMF) Observational StudyCompletedNCT02047097
• RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVERCompletedNCT02029729Phase 1
• RTA 408 Lotion in Healthy VolunteersCompletedNCT02029716Phase 1
• Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.CompletedNCT01978652Phase 1
• Ireland Natalizumab (TYSABRI) Observational ProgramCompletedNCT01943526
• A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male VolunteersCompletedNCT01943513Phase 1
• A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported OutcomesCompletedNCT01930708Phase 4
• Daclizumab Japanese PK StudyCompletedNCT01929746Phase 1
• BG00012 Regional Absorption StudyCompletedNCT01924832Phase 1
• A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple SclerosisCompletedNCT01917019Phase 3
• PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice DailyCompletedNCT01915901Phase 1
• Biogen Multiple Sclerosis Pregnancy Exposure RegistryCompletedNCT01911767
• Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMSCompletedNCT01903291
• Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral NeuropathyCompletedNCT01893125Phase 2
• PK and PD Study of Natalizumab in Pediatric Subjects With RRMSCompletedNCT01884935Phase 1
• BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar RadiculopathyCompletedNCT01873404Phase 2
• Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic NeuralgiaCompletedNCT01848730Phase 2
• Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)CompletedNCT01842126Phase 1
• An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01838668Phase 3
• An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)CompletedNCT01780246Phase 1
• A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy VolunteersCompletedNCT01749098Phase 1
• Functional MRI in Lupus NephritisCompletedNCT01731054
• Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsTerminatedNCT01706107
• Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval VolunteersCompletedNCT01689116Phase 1
• Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's DiseaseTerminatedNCT01677572Phase 1
• A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes MellitusWithdrawnNCT01655186Phase 2
• BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic DrugsWithdrawnNCT01652937Phase 2
• Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution FormulationCompletedNCT01646840Phase 1
• Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.CompletedNCT01632449Phase 1
• Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy VolunteersCompletedNCT01610310Phase 1
• An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy VolunteersCompletedNCT01598363Phase 1
• Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.CompletedNCT01597297Phase 2
• A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal DialysisWithdrawnNCT01576887Phase 2
• Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic FunctionCompletedNCT01563562Phase 1
• Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral RadiculopathyCompletedNCT01561027Phase 2
• MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and ColombiaCompletedNCT01556685Phase 4
• Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 DiabetesWithdrawnNCT01551446Phase 1
• Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedNCT01549769Phase 1
• A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal NeuralgiaCompletedNCT01540630Phase 2
• Fampridine Pregnancy Exposure RegistryTerminatedNCT01532154
• A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing LossCompletedNCT01518920Phase 1
• A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With SchizophreniaCompletedNCT01518894Phase 1
• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy VolunteersCompletedNCT01511510Phase 1
• A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male SubjectsCompletedNCT01503866Phase 1
• A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedNCT01500798Phase 1

← Biogen overview and focus areas